Granular proteins of eosinophils

Allergologia et Immunopathologia

Volumn 24, Issue 5, 1996, Pages 219-225

  Monteseirin J ^a,b   Prados, M ^a   Bonilla, I ^a   Llamas, E ^a   Delgado, J ^a   Sanchez Monteseirin H ^a   Chaparro, A ^a   Conde, J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EOSINOPHIL GRANULE PROTEIN; EOSINOPHIL PEROXIDASE; EOSINOPHIL PROTEIN X; LYSOPHOSPHOLIPASE; PEROXIDASE; PLASMA PROTEIN; RIBONUCLEASE;

ANIMAL; CELL GRANULE; CHEMISTRY; CYTOTOXICITY; EOSINOPHIL; FEMALE; HUMAN; MALE; METABOLISM; PHYSIOLOGY; PREGNANCY; REVIEW; ULTRASTRUCTURE;

ANIMALS; BLOOD PROTEINS; CYTOPLASMIC GRANULES; CYTOTOXICITY, IMMUNOLOGIC; EOSINOPHIL GRANULE PROTEINS; EOSINOPHIL PEROXIDASE; EOSINOPHIL-DERIVED NEUROTOXIN; EOSINOPHILS; FEMALE; HUMANS; LYSOPHOSPHOLIPASE; MALE; PEROXIDASES; PREGNANCY; RIBONUCLEASES;

EID: 0030226862     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Gleich GJ, Loegering DA, Kueppers F. Physiochemical and biological properties of the major basic protein from guinea pig eosinophil granules. J Exp Med. 1974;140'313-318.
2. Ackerman SJ, Loegering DA, Venge P. Distinctive cationic proteins of the human eosinophil granule:major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin J Immunol. 1983;131:2977-2984.
3. Wasmoen TL, Bell MP, Loegering DA, Gleich GJ, Pendergrast FG, McKean DJ. Biochemical and amino acid sequence analysis of human eosinophil granule major basic protein. J Biol Chem. 1988;263:12559-12563
4. Gleich G, Loegering D, Mann K, Maldonado J. Comparative properties of the Charcot-Leyden Crystal Protein and the Major Basic Protein from human eosinophils. J Clin invest. 1976,57.633-640.
5. Peters MS, Gleich GJ, Dunnette SL, Fukuda T. Ultrastructural study of eosinophils from patients with the hypereosinophilic syndrome: a morphological basis of hypodense eosinophils. Blood. 1988;71:780-785.
6. Gleich GJ, Pease LR, McKean DJ, Loegering DA, Wasmoen TL, Ten RM, Barker RL Análisis estructural de la secuencia de ammoácidos y de la secuencia de nucleótidos del cDNA de la proteina básica principal de los gránulos eosinófilos: predicción de una nueva molécula de pro-PBP En: Ancora S.A. (Eds). Esinófilos, Alergia y Asrna. Barcelona 1992;1-10.
7. Ackerman SJ, Kephart GM, Habermann TM Localization of eosinophil granule major basic protein in human basophils. J Exp Med. 1983;158:946-954.
8. Dvorak AM, Klebanoff SJ, Henderson WR. Vesicular uptake of eosinophil peroxidase by guinea pig basophils and by cloned mouse mast cells and granule-containing lymphoid cells. Am J Pathol 1985,118.425-432.
9. Slifman NR, Adolphson ChR, Gleich GJ Eosinófilos: aspectos bioquimicos y celulares. En: Salvat Editores S.A. I Alergia principios y práctica. Barcelona 1992:169-194.
10. Wasmoen TL, Wagner JM, Bartemes KR, Gleich GJ. Plasma levels of eosinophil granule major basic protein in pregnant cynomolgus monkeys. Placenta. 1992,13.265-272.
11. Butterworth AE, Wassom DL, Gleich GJ, Loegering DA, David JR. Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein J Immunol. 1979;122:221-229.
12. Wassom DL, Gleich GJ. Damage to Trichinella spiralis newborn larvae by eosinophil major basic protein. Am J Trop Med Hyg. 1987;28:860-866.
13. Hamman KJ, Barker RL, Loegering DA, Gleich GJ. Toxicity of purified human eosinophil granule protein for newborn larvae of trichineila spiralis. J Parasitol. 1987;73:523-529
14. Barker RL, Hamman SCJ, Checkel JL. Toxicity of purified human eosinophil granule proteins for microfilariae of Brugia malayi and Brugia pahangi. Fed Proc 1987,46:615-621.
15. Hamann KJ, Gleich G, Checkel J, Loegering D, McCall J, Barker R. In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol. 1990;134:3166-3173.
16. Kierszenbaum F, Ackerman SJ, Gleich GJ. Destruction of bloodstream forms of Trypanosoma cruzi by eosinophil granule major basic protein Am J Trop Med Hyg 1981;30:775-782
17. Abu-Ghazaleh RI, Gleich GJ, Prendergast FG. Interaction of eosinophil granule major basic protein with synthetic lipid bilayers. a mechanism for toxicity. J Membr Biol. 1992;128.153-164.
18. Thomas L, Zheutlin L, Gleich G. Pharmacological control of human basophil histamine release stimulated by eosinophil granule major basic protein. Immunology. 1989;66 611-615.
19. O'Donnel M, Ackerman S, Gleich G, Thomas L. Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J Exp Med. 1983;157:1981-1991.
20. Okayama Y, EI-Lati S, Leiferman K, Church M. Eosinophil granule proteins inhibit substance P-induced histamine release from human skin mast cells J Allergy Clin Immunol. 1994, 93:900-909.
21. Rohrbach MS, Wheatley CL, Slifman NR, Gleich GJ Activation of platelets by eosinophil granule proteins. J Exp Med. 1990;172:1271-12744.
22. Moy JN, Gleich GJ, Thomas LL Noncitotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release. J Immunol. 1990;145.2626-2632.
23. Rankin J, Harris P, Ackerman S. The effects of eosinophil-granule major basic protein on lung-macrophage superoxide anion generation J Allergy Clin Immunol 1992;9:746-752.
24. Gleich GJ. The eosinophil and bronchial asthma, current understanding. J Allergy Clin Immunol. 1990,85:422-436
25. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates J Clin Invest. 1991;88.1470-1473.
26. White SR, Ohno S, Munoz NM, Gleich GJ, Abrahams C, Solway J, Leff AR. Epithelium-dependent contraction of airway smooth muscle caused by eosinophil MBP. Am J Physiol Lung Cell Mol Physiol 1990; 259:294-303
27. Uchida D, Ackerman S, Coyle A, Larsen G, Weller P, reed J, Irvin C. The effect of human eosinophil granule Major Basic Protein on airway responsiveness in the rat in vivo Am Rev Respir Dis. 1993,147.982-988.
28. Coyle A, Ackerman S, Irvin C. Cationic proteins induce airway hyperresponsiveness dependent on charge interactions Am Rev Respir Dis. 1993;147:896-900.
29. Moy J, Thomas L, Whisler L. Eosinophil major basic protein enhances the expression of neutrophil CR3 and p150,95. J Allergy Clin Immunol. 1993,92:598-606.
30. Butterfteld JH, Weiler D, Peterson FA, Gleich GJ, Leiferman KM. Sequestration of eosinophil major basic protein in human mast cells. Lab Invest. 1990;62:77-86.
31. Barker RL, Gundel RH, Gleich GJ, Checkel JL, Loegering DA, Pease LR, Hamman KJ. Acidic polyamino acids inhibit human eosinophil granule major basic protein toxicity. Evidence of a functional role for ProMBP. J Clin Invest. 1991; 88 798-805
32. Moqbel R, Barkans J, Bradley BL, Durham SR, Kay AB. Application of monoclonal antibodies against major basic protein eosinophils in bronchial biopsies from atopic asthma. Clin Exp Allergy. 1992;22:265-273.
33. Peters MS, Rodríguez M, Gleich GJ. Localization of human eosinophil granule major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin by immunoelectron microscopy. Lab Invest. 1986;4:656-663
34. Egesten A, Alumets J, von Mecklenburg L Localization of eosinophil cationic protein, major basic protein, and eosinophil peroxidase in human eosinophil by immunoelectron microscopic technique. J Histochem Cytochem 1986;34:1399-1410
35. Kieerszenbaum F, Villalta F, Tai PC. Role of inflammatory cells in Chagas disease. III. Kinetics of human eosinophil activation upon interaction with parasites (Trypanosoma cruzi) J Immunol 1986;136:662-666
36. Barker RL, Loegering DA, Ten RM, Hamman KJ, Pease LR, Gleich GJ. Eosinophil cationic protein cDNA: comparison with other toxic cationic proteins and ribonucleases J Immunol. 1989; 143 952-955.
37. Olsson I, Persson AM, Winqvist I. Biochemical properties of the eosinophil cationic protein and demonstration of its biosynthesis in vitro in marrow cells from patients with an eosinophilia Blood 1986;67:498-503
38. Gleich GJ, Loegering DA, Bell MP, Checkel JL, Ackerman SJ, Mc Kean DJ. Biochemical and functional similarities between eosinophil-derived neurotoxin and eosinophil cationic protein homology with ribonuclease. Proc Natl Acad Sci USA. 1986;83:3146-3150
39. Spry CJF. Eosinophils A comprehensive review, and guide to scientific and medical literature. Oxford University Press, 1988
40. Winqvist I, Olofsson T, Olsson I Mechanism for eosinophil degranulation;release of the eosinophil cationic protein. Immunology. 1984;54:1-8
41. Venge P, Roxin LE, Olsson I. Radioimmunoassay of human eosinophil cationic protein. Br J Hematol. 1977;37:331-335.
42. Peterson CG, Enander I, Nystrand J, Anderson AS, Nilsson L, Venge P. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method Establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy 1991;21:561-567.
43. Reimert CM, Venge P, Kharazmi A, Bendtzen K. Detection of eosinophil cationic protein (ECP) by an enzyme-linked immunosorbent assay J Immunol Methods 1991;138:285-290.
44. Kurihara K, Yamada T, Saito H, Iikura Y Basic research into the measurement of eosinophil cationic protein (ECP) in blood samples. Arerugi. 1992;41 512-518.
45. Slifman N, Loegering D, McKean D, Gleich G Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol. 1986;137:2913-2917.
46. Tai PC, Spry CJ, Peterson C, Venge P, Olsson I. Monoclonal antibodies distinguish between storage and secrete forms of eosinophil cationic protein. Nature 1984;309:182-184.
47. Tai PC, Holt M, Denny P, Gibbs A, Williams B, Spry C. Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis.the Churg-Stauss syndrome. Br Med J. 1984,289:400-402.
48. Tai PC, Spry C, Olsen E, Ackerman SJ, Dunnette S, Gleich G. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987;2:643-647.
49. Slifman N, Venge P, Peterson C, McKean D, Gleich G. Human eosinophil-derived neurotoxin and eosinophil protein X are likely the same protein J Immunol. 1989;143:2317-2322
50. Fredens K, Dybdahl H, Dahl R, Baandrup U. Extracellular deposit of the cationic proteins ECP and EPX in tissue infiltrations of eosinophils related to tissue damage. APMIS 1988;96:711-719.
51. Rosenberg H, Gallin J. Neutrophil-Specific Granule Deficiency includes Eosinophils. Blood. 1993;82:268-273
52. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamman KJ, Gleich GJ Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol. 1989;142 4428-4434.
53. Ackerman SJ, Gleich GJ, Loegering DA, Richardson BA, Butterworth AE. Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of schistosoma mansoni Am J Trop Med Hyg 1985;34:735-745.
54. Young DE, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 1986;321:613-616.
55. Särnstrand B, Westergren-Thorsson G, Hernäs J, Peterson CGB, Venge P, Malmström A. Eosinophil cationic protein and transforming growth factor-A stimulates synthesis of hyaluronan and proteoglycan in human fibroblast cultures. Proceedings of the 5th International Colloquium on Pulmonary Fibrosis, Abstract.
56. Lundgren JD, Davey RT Jr, Lundgren B, Mullol J, Marom Z, Logun C, Baraniuk J, Kaliner MA, Shelhamer JH. Eosinophil cationic protein stimulates and major basic protein inhibits airway mucus secretion. J Allergy Clin Inmunol. 1991;87:689-698
57. Peterson CG, Skoog V, Venge P. Human eosinophil cationic protein (ECP and EPX) and their suppressive effects on lymphocyte proliferation. Immunobiology. 1986;171:1-13.
58. Dahl R, Venge P. Activation of blood coagulation during inhalation challenge tests. Allergy. 1981;36.129-133.
59. Venge P, Dahl R, Hàligren R, Olsson I. Cationic protein of human eosinophils and their role in the inflammatory reaction In: The eosinophil in health and disease Mahmoud A, Austen K, eds. Grune and Stratton, New York. 1980:131-146.
60. Fredens K, Dahl R, Venge P. In vitro studies of the interaction between heparin and eosinophil cationic protein. Allergy. 1991;46:27-29.
61. Peterson CGB, Venge P. Interaction and complex formation between the eosinophil cationic protein (ECP) and alpha-2-macroglobulin. Biochem J. 1987;245:781-787.
62. Dahl R, Venge P, Fredens K. Eosinophils. In: Asthma: basic mechanisms and clinical Academic Pres, London, 1988:115-129.
63. Venge P. Human eosinophil granule proteins: structure, function and release. In:Immunopharmacology of eosinophils Smith H, Cook R, eds. Academic Press, London. 1993:43-55.
64. Weiler JM, Edens RE, Gleich GJ Eosinophil granule cationic proteins regulate complement. I Activity on the alternative pathway. J Immunol. 1992;149:643-648.
65. Altman L, Ayars G, Baker C, Luchtel D Cytokines and eosinophil derived cationic proteins upregulate intercellular adhesion molecule-1 on human nasal epithelial cells. J Allergy Clin Immunol. 1993;92-527-536.
66. Juhlin L, Venge P. Eosinophilic cationic protein (ECP) in skin disorders. Acta Derm Venerol. 1991;71:495-501.
67. Fredens K, Dahl R. and Venge P. The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein-X. J Allergy Clin Immunol. 1982;70:361-366
68. Gordon MH. Remarks on Hodgkin's disease. A pathogenic agent in the glands, and its application in diagnosis. Br Med J. 1933;1:641-644.
69. King LS. Encephalopathy following injections of bone marrow extract. J Exp Med. 1939;70:303-314.
70. Turner JC, Jackson H Jr, Parker F Jr. The etiologic relation of the eosinophil to the Gordon phenomenon in Hodgkin's disease Am J Med Sci. 1938;195:27-32.
71. Durack DT, Akerman SJ, Loegering DA, Gleich GJ. Purification of human eosinophil-derived neurotoxin. Proc Natl Acad Sci USA. 1981;78:5165-5169.
72. Peterson C, Venge P. Purification and characterization of a new cationic protein-eosinophil protein-X(EPX)-from granules of human eosinophils Immunology. 1983,50:19-26
73. Gullberg U, Widegren B, Arnason U, Egesten A, Olsson I. The cytotoxic eosinophil cationic protein (ECP) has ribonuclease activity. Biophys Res Commun. 1986;139:1239-1242.
74. Kay AB T lymphocytes and their products in atopic allergy and allergy. Int Arch Allergy Appl Immunol 1991;94:189-93.
75. Bolscher BG, Plat H, Wever R. Some properties of human eosinophil peroxidase, a comparison with other peroxidases. Biochim Biophys Acta 1984;784:177-186.
76. Carlson MG, Peterson CG, Venge P. Human eosinophil peroxidase. purification and characterization. J Immunol. 1985;134:1875-1879.
77. Enomoto T, Kitani T. Electron microscopic studies on peroxidase and acid phosphatase reaction in human leukocytes in normal and leukemic cells on phagocytosis Acta Haemat Jap. 1966;29.554-570.
78. Klebanoff SJ, Jong EC, Henderson WRJr. The eosinophil peroxidase: purification and biological properties. In. Mahmoud A.A.F, Austen K.F.(Eds.). The eosinophil in health and disease.Grune & Stratton, Inc. New York. 1980;99-114.
79. Sánchez ML, Martín T, Mateos F, García-Salgado M J, Pérez Arellano JL. Radicales libres de oxígeno y células del sistema mononuclear fagocitico. Inflamación. 1993,4:166-175.
80. Presentey B, Szapiro L. Hereditary deficiency of peroxidase and phospholipids in eosinophilic granulocytes Acta Haematol. 1969;41:359-362.
81. Hisamatsu KI, Ganbo T, Nakazawa T, Murakami Y, Gleich GJ, Makiyama K, Koyama H. Cytotoxicity of human eosinophil granule major basic protein to human nasal sinus mucosa in vitro. J Allergy Clin Immunol. 1990:86.52-63.
82. Slungaard A, Maloney JR Jr. Bromide-dependent toxicity of eosinophil peroxidase for endothelium and isolated working rat hearts,a model for eosinophilic endocarditis. J Exp Med 1991;173:117-126.
83. Venge P. Human eosinophil granule proteins: structure, function and release. In. Immunopharmacology of eosinophils Smith H, Cook R, eds. Academic Press, London. 1993:43-55.
84. Yoshikawa S, Kayes S, Parker J. Eosinophils increase lung microvascular permeability via the Peroxidase-Hydrogen Peroxide-Halide System. Bronchoconstriction and vasoconstriction unaffected by eosinophil peroxidase inhibition. Am Rev Respir Dis. 1993;147 914-920.
85. Ackerman SJ, Kephart GM, Habermann TM. Localization of eosinophil granule major basic protein in human basophils. J Exp Med. 1983;158:946-953
86. Dvorak AM, Letourneau L, Login GR, Weller PF, Ackerman SJ Ultrastructural localization of the Charcot-Leyden crystal protein (lysophospholipase) to a distinct crystalloid-free granule population in mature human eosinophils. Blood. 1988;72:150-158
87. Weller PF, Goetzl EJ, Austen KF. Identification of human eosinophil lysophospholipase as the constituent of Charcot-Leyden crystals. Proc Natl Acad Sci USA. 1980;77:7440-7443.
88. Weller PF, Bach D, Austen KF. Human eosinophil lysophospholipase. the sole protein component of Charcot-Leyden crystals J Immunol. 1982;128.1346-1349.
89. Fukuda T, Ackerman S, Reed C, Peters M, Dunnette S, Gleich G. Calcium ionophore A23187 calcium-dependent cytolytic degranulation in human eosinophils. J Immunol. 1985;135:1349-1356.
90. Ackerman SJ, Loegering DA, Gleich GJ The human eosinophil Charcot-Leyden crystal protein: biochemical characteristics and measurement by radioimmunoassay J Immunol. 1980,125 2118-2126.
91. Ackerman SJ, Correte SF, Rosenberg HT, Bennett J, Mastrianni DM, Nicholson-Weller A, Weller PF, Chin DT, Tenen DG. Molecular clonning and characterization of human Eosinophil Charcot-Leyden Cristal Protein (Lysophospholipase). Similarities to IgE Binding Proteins and the S-Type Animals Lectin Superfamily. J Immunol. 1993;150-456-468
92. Weller PF, Wasserman SI, Austen KF Selected enzymes preferentially present in the eosinophil. In the eosinophil health and disease (eds. A A. Mahmoud,K F Austen and A S Simon) Grune and Stratton, New York. 1980.115-130.
93. Dvorak AM, Furitsu T, Letourneau L, Ishizaka T, Ackerman SJ. Mature eosinophils stimulated to develop in human cord blood mononuclear piecemeal degranulation of specific granules and distribution of Charcot-Leyden crystal protein. Am J Pathol. 1991;138:69-82.
94. Ackerman SJ, Zhou Z, Tenen DG, Clark MA, Tu YP, Irvin CG. Human Eosinophil Lysophospholipase (Charcot Leyden Crystal Protein): molecular cloning, expression, and potential function in asthma. In: Eosinophils in allergy and inflammation. Gleich G.J, Kay A.B. eds Marcel Dekker, Inc. New York. 1994:21-54.
95. Aumuller G, Seitz J. Cytochemistry and biochemistry of acid phosphatases. VI. Immunoelectron microscopic studies on human prostatic and leukocytic acid phosphatases. Prostate. 1985:7.161-169.
96. Bass DA, Grover WH, Lewis JC, Szejda P, DeChatelet LR, McCall CE. Comparison of human eosinophils from normals and patients with eosinophilia. J Clin Invest 1980,66:1265-1273.
97. Davis WB, Fells GA, Sun XH, Gadek JE, Venet A, Crystal RG. Eosinophil-mediated injury to lung parenchymal cells and interstitial matrix: a possible role for eosinophil in chronic inflammatory disorders of the lower respiratory tract J Clin Invest. 1984;74:269-278.
98. Bainton DF, Farquhar MG. Segregation and packaging of granule enzymes in eosinophilic leukocytes. J Cell Biol. 1970;45:54-73.
99. Egesten A, Weller PF, Olsson I Arylsulfatase B is present in crystalloid-containing granules of human eosinophil granulocytes. Int Arch Allergy Immunol. 1994;104:207-210.
100. Zeiger RS, Yurdin DL, Colten HR. Histamine metabolism. II Cellular and subcellular localization of the oatabolic enzymes, histaminase and histamme methyl transferase, in human leukocytes J Allergy Clin Immunol. 1976;58:172-179.
101. Iozzo RV, MacDonald GH, Wight TN. Immunoelectron microscopic localization of catalase in human eosinophilic leukocytes. Histochem Cytochem 1982,30.697-701.
102. Pihl E, Gustafson GT, Joseffson B, Paul KG. Heavy metals in granules of eosinophilic granulocytes. Scand J Haematol. 1967:4:371-379.